Qiagen has acquired an exclusive worldwide license to a promising biomarker that could aid the diagnosis of a group of blood disorders.
The biomarker calreticulin (CALR) has been found to present mutations in an estimated 15 percent of cases of myeloproliferative neoplasms, a group of blood disorders involving overproduction of blood cells that can cause severe complications.